

Technical data

CINITAPRIDE 1

Cinitapride 1mg tablets



General Information	
Drug Name	Cinitapride
Generic Name	Cinitapride 1 mg Tablets
Qualitative-Quantitative Composition	Each tablet contains: Cinitapride hydrogen tartrate..... 1.37 mg Equivalent to Cinitapride.....1 mg Excipients q.s.c.
Pharmaceutical Form	Tablet
Clinical Data	
- Therapeutic Indications	- Treatment of mild-moderate dyspepsia dysmotility type. - As coadjuvant treatment of gastroesophageal reflux in patients in whom proton pump inhibitors have been shown to be insufficient.
- Method of Administration	Oral
- Contraindications	Hypersensitivity to the active ingredient or to any of the excipients. Cinitapride should not be administered to patients in whom the stimulation of gastric motility may be harmful, either by the presence of bleeding, obstruction or perforation, or to patients with proven tardive dyskinesia to neuroleptics.
Presentation	Box with 10, 30, 50, 100, 100, 500 and 1000 Tablets
Incompatibilities	Not applicable
Prescription regime	Adults (over 20 years of age): 1 tablet, 3 times a day, 15 minutes before each meal. It is neither more effective nor convenient to increase the recommended dose. Pediatric population According to bibliographic reference, safety and efficacy in children and adolescents have not been established. Its use is not recommended in this age group.
Storage Condition	Store at temperatures below 30°C. Keep out of reach of children.
Special legends	Patients with hereditary galactose intolerance, Lapp lactase insufficiency (insufficiency observed in certain Lapland populations) or glucose or galactose malabsorption should not take this drug.
Approved countries	Honduras, El Salvador
Manufacturer Laboratory	SAG Manufacturing S.L.U., España
Revision Date	May 10th, 2022